Anjalee Khemlani

3 weeks ago | aol.com | Anjalee Khemlani

Omada Health (OMDA) has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion. The company follows a successful launch of Hinge Health (HNGE) last month, which plays in one of the same markets as Omada — musculoskeletal health guidance. But Omada is better known as a clinical health guidance company for multiple chronic diseases, with an emphasis lately on weight loss management.

3 weeks ago | yahoo.com | Anjalee Khemlani

CVS Health (CVS) is spending $20 billion in the next 10 years to upgrade to a more tech-enabled consumer health experience, a move the company says will help address the friction in America’s troubled healthcare system. The investment, Yahoo Finance has learned, will not just impact CVS and its vertically integrated businesses, including the pharmacy, health providers, and insurer Aetna. It will also allow competitors and other players in the sector to plug into the CVS system.

4 weeks ago | aol.com | Anjalee Khemlani

Moderna's (MRNA) stock was up slightly in pre-market trading Thursday despite an announcement that the National Institutes of Health (NIH), led by Robert F. Kennedy Jr., is ending a $750 million-plus contract to develop its bird flu vaccine late Wednesday. "Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines," Moderna said in a statement late Wednesday.

1 month ago | ca.finance.yahoo.com | Anjalee Khemlani

Hinge Health (HNGE), a digital health platform for physical therapy, debuted on the New York Stock Exchange at $32 per share Thursday and rising shortly after trading to $39. The company announced it would go public in March, marking the second time it would attempt to do so. It was valued at nearly $6.2 billion in 2022, when it first announced plans. Hinge aimed for a $3 billion valuation for Thursday, offering 13.7 million shares on the market.

1 month ago | ca.finance.yahoo.com | Anjalee Khemlani

Novo Nordisk (NVO) is offering a one-month reduction in the price of its blockbuster weight-loss GLP-1 drug, to help encourage new patients to use the branded drug, as compounded copycats are forced off the market. "This one-time offer is intended to help patients who have previously been prescribed unapproved or illicit 'semaglutide' drugs and are seeking access to authentic, FDA-approved Wegovy," the company said in a statement Thursday.